DOCSLIB.ORG

YTN Ci Y COOCH3 --Al-E- F 7.1% F 5 6

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
YTN Ci Y COOCH3 --Al-E- F 7.1% F 5 6 USOO5853696A United States Patent (19) 11 Patent Number: 5,853,696 Elmaleh et al. (45) Date of Patent: Dec. 29, 1998 54 SUBSTITUTED 2-CARBOXYALKYL-3 Carroll et al., “Synthesis, Ligand Binding, QSAR, and (FLUOROPHENYL)-8-(3-HALOPROPEN-2- CoMFA Study . , Journal of Medicinal Chemistry YL) NORTROPANES AND THEIR USE AS 34:2719-2725, 1991. IMAGING AGENTS FOR Madras et al., “N-Modified Fluorophenyltropane Analogs. NEURODEGENERATIVE DISORDERS ... ", Pharmcology, Biochemistry & Behavior 35:949–953, 1990. 75 Inventors: David R. Elmaleh; Bertha K. Madras, Milius et al., “Synthesis and Receptor Binding of N-Sub both of Newton; Peter Meltzer, stituted Tropane Derivatives . , Journal of Medicinal Lexington; Robert N. Hanson, Newton, Chemistry 34:1728-1731, 1991. all of Mass. Boja et al. “New, Potent Cocaine Analogs: Ligand Binding 73 Assignees: Organix, Inc., Woburn; The General and Transport Studies in Rat Striatum' European J. of Hospital Corporation, Boston; The Pharmacology, 184:329–332 (1990). President and Fellows of Harvard Brownell et al. *Use of C-11 College, Cambridge; Northeastern 2B-Carbomethoxy-3B-4-Fluorophenyl Tropane (C-11 University, Boston, all of Mass. CFT) in Studying Dopamine Fiber Loss in a Primate Model of Parkinsonism” J. Nuclear Med. Abs., 33:946 (1992). 21 Appl. No.: 605,332 Canfield et al. “Autoradiographic Localization of Cocaine Binding Sites by HICFT (I HIWIN 35,428) in the 22 Filed: Feb. 20, 1996 Monkey Brain” Synapse, 6:189-195 (1990). Carroll et al. “Probes for the Cocaine Receptor. Potentially Related U.S. Application Data Irreversible Ligands for the Dopamine Transporter” J. Med. 62 Division of Ser. No. 142.584, Oct. 25, 1993, Pat. No. Chem., 35:1813–1817 (1992). 5,493,026. Carroll et al. “Cocaine Receptor: Biochemical Characteriza tion and Structure-Activity Relationships of Cocaine Ana (51) Int. Cl." ..................................................... A61K 51/04 logues at the Dopamine Transporter” J. Med. Chem., 52 U.S. Cl. .......................................... 424/1.85; 424/1.89 35:969–981 (1992). 58 Field of Search .................................. 424/1.85, 1.89, Carroll et al. “Synthesis, Ligand Binding, QSAR, and 424/1.65; 546/132; 514/304 COMFA Study of 3.3-(p-Substituted phenyl)tropane-2B-carboxylic Acid Methyl Esters' J. Med. 56 References Cited Chem., 34:2719–2725 (1991). U.S. PATENT DOCUMENTS (List continued on next page.) 3,452,029 6/1969 Childress et al. ....................... 260/292 5,128,118 7/1992 Carroll et al. ... ... 424/1.1 Primary Examiner John Kight 5,268,480 12/1993 Kozikowski .............................. 546/23 Assistant Examiner-Lara Chapman Kelley 5,310,912 5/1994 Neumeyer et al. .. ... 546/132 Attorney, Agent, or Firm Fish & Richardson P.C. 5,413,779 5/1995 Kuhar et al. ............. ... 424/1.85 5,439,666 8/1995 Neumeyer et al. ...... ... 424/1.85 57 ABSTRACT 5,493,026 2/1996 Elmaleh et al. ..... ... 346/132 5,496,953 3/1996 Kuhar et al. ............................ 54.6/125 Disclosed are certain cocaine analogs useful for imaging of cocaine receptors and dopamine receptors. Also disclosed OTHER PUBLICATIONS are analogs useful for imaging diagnostics for Parkinson's Abstract #275, “Radioiodinated 2beta-Carbomethoxy disease. 3beta (4-Chlorophenyl)-8-(3E-and 3Z-Iodopropen-2-yl) Nortropanes”, Journal of Nuclear Medicine 33:890, 1992. 4 Claims, 3 Drawing Sheets H YN (Bu)3Sn COOCH3 YTN ci Y COOCH3 --al-e- F 7.1% F 5 6 NS 87% Atropane 5,853,696 Page 2 OTHER PUBLICATIONS Milius et al. “Synthesis and Receptor Binding of N-Substi tuted Tropane Derivatives. High-Affinity Ligands for the Elmaleh et al. “PET Imaging Probes for the Cocaine Recep tors: A Validation Study in a Nonhuman Primate Model” J. Cocaine Receptor" J. Med. Chem., 34:1728-1731 (1991). Nuclear Med. Abs., 33:946 (1992). Reith et al. “Radiolabeling of Dopamine Uptake Sites in Goodman et al. "Radioiodinated Mouse Striatum: Comparison of Binding Sites for Cocaine, 2B-Carbomethoxy-3?-(4-Chlorophenyl)-8-(3E-and MaZindol, and GBR 12935” Arch. of Pharmacol., 3Z-Iodopropen-2-YL)Nortropanes: Synthesis of Potential 345:309-318 (1992). Radioligands for Mapping Cocaine Receptor...' J. Nuclear Reith et al. “Structural Requirements for Cocaine Congeners Med. Abs., 33:890 (1992). to Interact with Dopamine and Serotonin Uptake Sites in Kaufman et al. “Severe Depletion of Cocaine Recognition Mouse Brain and to Induce Sterotyped Behavior Biochem. Sites Associated With the Dopamine Transporter in Pharmacol., 35:1123–1129 (1986). Parkinson’s-Diseased Striatum' Synapse, 9:43–49 (1991). Isacson, “Clinical and Preclinical PET Correlates of Parkin Madras “' C-WIN35,428 for Detecting Dopamine Deple sonism with '' C-Win 35,428” Annals of Neurology, tion in Mild Parkinson's Disease' Annals of Neuro., 35:377-378 (1994). 35;376-379 (1994). Meyer et al. “Intravenously Administered Dopamine Trans Madras et al. “N-Modified Fluorophenyltropane Analogs of porter Site Radioligand Is Not Significantly Retained in Cocaine With High Affinity for Cocaine Receptors' Phar Mouse Substantia Nigra or Other Sites Outside of Basal macol. Biochem. & Behav., 35:949–953 (1990). Ganglia.” Annals of Neurology, 35:378-379 (1994). Meltzer et al. “Substituted 3-Phenyltropane Analogs of Van der Zee et al., “A comparison of the inhibitory effects of Cocaine: Synthesis, Inhibition of Binding at Cocaine Rec aromatic Substituted benzhydryl . into Synaptosomal ognition Sites, and Positron Emission Tomography Imag preparations of the rat brain”, Neuropharmacology, 17(7), ing” J. Med. Chem., 36:855–862 (1993). 483-90, 1978. U.S. Patent Dec. 29, 1998 Sheet 2 of 3 5,853,696 U.S. Patent Dec. 29, 1998 Sheet 3 of 3 5,853,696 SIN %/8 5,853,696 1 2 SUBSTITUTED 2-CARBOXYALKYL-3 ('I-iodopropene-2yl) nortropane. The selectivity of this (FLUOROPHENYL)-8-(3-HALOPROPEN-2- analog for the dopamine over the Serotonin transporter is not YL) NORTROPANES AND THEIR USE AS discussed. IMAGINGAGENTS FOR CFT or WIN 35,428 is approximately 15 times more NEURODEGENERATIVE DISORDERS Selective for the dopamine over the Serotonin transporter. The 4-chloro analog is 4-fold selective. See Carroll et al., J. This is a divisional of application Ser. No. 08/142.584, Med. Chem. 35:969 (1992); and Meltzer et al., J. Med. filed Oct. 25, 1993, now U.S. Pat. No. 5,493,026. Chem. 36:855–862 (1993). SUMMARY OF THE INVENTION BACKGROUND OF THE INVENTION 1O We have discovered that fluorination of the phenyl Sub Stituent of N-haloallyl phenyl nortropanes yields compounds The invention relates to Substituted nortropanes and their that are unusually effective for several purposes. The 3E and use to image: a) dopamine-transporter-containing neurons, 3Z isomers of 2-f-carbomethoxy-3-3-(4-fluorophenyl)-8- particularly in connection with diagnosis and Study of cer (3-I-iodopropen-2-yl) nortropane are particularly preferred. tain neurodegenerative disorders; and b) cocaine receptors. 15 We have designated this preferred compound Iodoaltropane There is a need for diagnostic agents and markers of or IACFT. Most preferably, the compounds according to the neurogenerative disorderS Such as Parkinson's disease. For invention are labeled with radionuclides of the halogen example, exclusion at an early stage of Parkinson's disease series, such as 'I or 'I. as the cause of Symptoms may be useful information in The Special properties of the claimed compounds are best diagnosing other conditions. Moreover, early diagnosis of understood with the following background. Cocaine recog Parkinson's disease can facilitate the introduction of puta nition sites are localized on the dopamine transporter, which tive prophylactic drug therapy (e.g., deprenyl) prior to the itself is localized on dopamine nerve terminals. Drugs that onset of more Severe Symptoms. See, Kaufman and Madras bind to these sites therefore have potential uses which (1991) Synapse 9:43-49. Detection of nerve cell depletion in include: (i) imaging probes for neurodegenerative disorders; the presymptomatic phase in an animal model of Parkin 25 and (ii) imaging probes for dopamine transporter/cocaine Son's disease would also be useful, e.g., when using the binding Sites. model to evaluate therapies for Parkinson's disease. See, Because of the unique anatomical location of the cocaine Hantraye et al. (1992) Neuro Reports 3:265-268; and recognition Sites, a high affinity probe for imaging of these sites in vivo in the brain can be carried out using PET or Hantraye et al. (1992) Soc. Neurosci. Abstra. 18:935. SPECT imaging. Such imaging is useful for diagnosing or There is a particular need for diagnostic agents and monitoring Parkinson's disease, a neurological disorder markers of neurogenerative disorders that Selectively target characterized by the degeneration of dopamine nerve termi a dopamine transporting protein (the dopamine transporter) nals or by aging. in preference to another protein known as the Serotonin Accordingly, one aspect of the invention features a com transporter. In normal brain tissue, the dopamine:Serotonin pound of formula: transporter density ratio is approximately 10:1. In certain 35 neurodegenerative disorders, Such as Parkinson's disease, I nerve cells that produce dopamine (and on which the dopamine transporter is located) undergo Severe depletion, HC=CHCH while Serotonin nerve cells are leSS affected. The dopamine: N COR serotonin transporter ratio can fall to 50% in Parkinson's 40 disease. Various Substances (particularly cocaine and cocaine congeners) are potent inhibitors of dopamine transport in the striatum of the brain because they bind to the dopamine F transporter. The more Strongly these Substances block 45 dopamine transport, the more Strongly they bind to Sites on wherein the following condition is imposed on that formula: the dopamine transporter which have been labeled by H) R is -CH, -CH2CH (C. configuration; f configuration cocaine or by a compound known as HICFT (also known or both), -CH(CH), -(CH), CH, -(CH2)CHX, as HIWIN 35.428). See, Madras et al., (1989) J.
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Current Topics in Behavioral Neurosciences
    Current Topics in Behavioral Neurosciences Series Editors Mark A. Geyer, La Jolla, CA, USA Bart A. Ellenbroek, Wellington, New Zealand Charles A. Marsden, Nottingham, UK For further volumes: http://www.springer.com/series/7854 About this Series Current Topics in Behavioral Neurosciences provides critical and comprehensive discussions of the most significant areas of behavioral neuroscience research, written by leading international authorities. Each volume offers an informative and contemporary account of its subject, making it an unrivalled reference source. Titles in this series are available in both print and electronic formats. With the development of new methodologies for brain imaging, genetic and genomic analyses, molecular engineering of mutant animals, novel routes for drug delivery, and sophisticated cross-species behavioral assessments, it is now possible to study behavior relevant to psychiatric and neurological diseases and disorders on the physiological level. The Behavioral Neurosciences series focuses on ‘‘translational medicine’’ and cutting-edge technologies. Preclinical and clinical trials for the development of new diagostics and therapeutics as well as prevention efforts are covered whenever possible. Cameron S. Carter • Jeffrey W. Dalley Editors Brain Imaging in Behavioral Neuroscience 123 Editors Cameron S. Carter Jeffrey W. Dalley Imaging Research Center Department of Experimental Psychology Center for Neuroscience University of Cambridge University of California at Davis Downing Site Sacramento, CA 95817 Cambridge CB2 3EB USA UK ISSN 1866-3370 ISSN 1866-3389 (electronic) ISBN 978-3-642-28710-7 ISBN 978-3-642-28711-4 (eBook) DOI 10.1007/978-3-642-28711-4 Springer Heidelberg New York Dordrecht London Library of Congress Control Number: 2012938202 Ó Springer-Verlag Berlin Heidelberg 2012 This work is subject to copyright.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder
    REVIEW The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder Natalia del Campo, Samuel R. Chamberlain, Barbara J. Sahakian, and Trevor W. Robbins Through neuromodulatory influences over fronto-striato-cerebellar circuits, dopamine and noradrenaline play important roles in high-level executive functions often reported to be impaired in attention-deficit/hyperactivity disorder (ADHD). Medications used in the treatment of ADHD (including methylphenidate, dextroamphetamine and atomoxetine) act to increase brain catecholamine levels. However, the precise prefrontal cortical and subcortical mechanisms by which these agents exert their therapeutic effects remain to be fully specified. Herein, we review and discuss the present state of knowledge regarding the roles of dopamine (DA) and noradrenaline in the regulation of cortico- striatal circuits, with a focus on the molecular neuroimaging literature (both in ADHD patients and in healthy subjects). Recent positron emission tomography evidence has highlighted the utility of quantifying DA markers, at baseline or following drug administration, in striatal subregions governed by differential cortical connectivity. This approach opens the possibility of characterizing the neurobiological underpinnings of ADHD (and associated cognitive dysfunction) and its treatment by targeting specific neural circuits. It is anticipated that the application of refined and novel positron emission tomography methodology will help to disentangle the overlapping and dissociable contributions of DA and noradrenaline in the prefrontal cortex, thereby aiding our understanding of ADHD and facilitating new treatments. Key Words: Attention-deficit/hyperactivity disorder, dopamine, DA and NA in the pathophysiology of ADHD, with a focus on the frontostriatal circuits, nigrostriatal projections, noradrenaline, pos- molecular neuroimaging literature.
    [Show full text]
  • Dopamine Transporter Imaging for the Diagnosis of Dementia with Lewy Bodies (Review)
    Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies (Review) McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 1 http://www.thecochranelibrary.com Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 3 OBJECTIVES ..................................... 5 METHODS ...................................... 5 RESULTS....................................... 8 Figure1. ..................................... 8 Figure2. ..................................... 10 Figure3. ..................................... 11 Figure4. ..................................... 11 Figure5. ..................................... 11 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 13 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 14 CHARACTERISTICSOFSTUDIES . 16 DATA ........................................ 21 Test 1. 123I-FP-CIT SPECT scan, analysed semi-quantitatively, in patients with dementia meeting clinical criteria for AD orDLBorboth.................................. 21 Test 2. 123I-FP-CIT SPECT scan, rated visually, in patients with dementia
    [Show full text]
  • Modafinil Occupies Dopamine and Norepinephrine Transporters in Vivo and Modulates the Transporters and Trace Amine Activity in V
    JPET Fast Forward. Published on August 2, 2006 as DOI: 10.1124/jpet.106.106583 JPET FastThis article Forward. has not beenPublished copyedited on and Augustformatted. 2,The 2006 final version as DOI:10.1124/jpet.106.106583 may differ from this version. JPET #106583 Modafinil Occupies Dopamine and Norepinephrine Transporters in vivo and Modulates the Transporters and Trace Amine Activity in vitro Bertha K. Madras, Zhihua Xie, Zhicheng Lin, Amy Jassen, Helen Panas, Laurie Lynch, Ryan Johnson, Eli Livni, Thomas J. Spencer, Ali A. Bonab, Gregory M. Miller and Alan J. Fischman Downloaded from Department of Psychiatry, Harvard Medical School and New England Primate Research Center, jpet.aspetjournals.org 1 Pine Hill Drive, Southborough, MA 01772-9102 (BKM, ZX, ZL, AJ, HP, LM, RJ, GMM), Massachusetts General Hospital, Boston, MA, 02114 (EL, TJS, AAB, AJF). at ASPET Journals on September 30, 2021 1 Copyright 2006 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on August 2, 2006 as DOI: 10.1124/jpet.106.106583 This article has not been copyedited and formatted. The final version may differ from this version. JPET #106583 Running title: Modafinil occupies the dopamine transporter in brain Corresponding author: Bertha K. Madras, PhD Department of Psychiatry, Harvard Medical School New England Primate Research Center 1 Pine Hill Drive, Southborough, MA 01772-9102 Downloaded from TEL: 508-624-8073 FAX: 508-624-8166 jpet.aspetjournals.org EMAIL: [email protected] at ASPET Journals on September 30, 2021 Abstract 244 Introduction 798 Discussion 1552 Text pages 34 Tables 2 Figures 8 References 53 Abbreviations: CFT: 2β-carbomethoxy-3β-4-(fluorophenyl)tropane; MeNER: (S,S)-2-(α-(2- methoxyphenoxy)benzyl)morpholine; PEA: phenethylamine; DAT: dopamine transporter; NET: 2 JPET Fast Forward.
    [Show full text]
  • Pain: Pathophysiology and Neuroscience
    PAIN: PATHOPHYSIOLOGY AND NEUROSCIENCE WWW. LP3 NETWORK. COM Pain: Pathophysiology and Neuroscience TABLE OF CONTENTS Accreditation ............................................................................................................................................................................... 4 Activity Description ........................................................................................................................................................................... 5 Learning Objectives .......................................................................................................................................................................... 5 Activity Facilitators ........................................................................................................................................................................... 7 Basic Structure and Function of the Nervous System ................................................................................................................... 8 Skeletal Structure of the Spinal Column & Vertebrae ..................................................................................................................... 10 Action Potential Conduction ........................................................................................................................................................... 12 Ion Channels ..................................................................................................................................................................................
    [Show full text]
  • Parkinson's Disease View Online At
    Parkinson's Disease View online at http://pier.acponline.org/physicians/diseases/d243/d243.html Module Updated: 2013-01-24 CME Expiration: 2016-01-24 Author Melissa Gaines, MD Table of Contents 1. Diagnosis ..........................................................................................................................2 2. Consultation ......................................................................................................................6 3. Hospitalization ...................................................................................................................11 4. Therapy ............................................................................................................................12 5. Patient Counseling ..............................................................................................................22 6. Follow-up ..........................................................................................................................23 References ............................................................................................................................28 Glossary................................................................................................................................37 Tables ...................................................................................................................................40 Figures .................................................................................................................................55
    [Show full text]
  • Anhedonia: Circuitry and Relevance to Drug Development & Patient Stratification
    The Neurobiology of Anhedonia: Circuitry and Relevance to Drug Development & Patient Stratification Diego A. Pizzagalli, Ph.D. Professor of Psychiatry Harvard Medical School McLean Hospital ISCTM Reward Processing February 21, 2020 Disclosures • Grant/Research Support: • NIH, NARSAD, Dana Foundation • Speaker’s Bureau: • None • Consultant: • Akili, BlackThorn Therapeutics (licensed Probabilistic Reward Task), Boehringer Ingelheim, Compass Pathway, Otsuka, Takeda • Stock Options: • BlackThorn Therapeutics • Patents: • None Role of Anhedonia in MDD & Antidepressant Response 1) Anhedonia predicts: • Depression two years later (e.g., Wardenaar et al. 2012); • Poor outcome (e.g., Spijker et al. 2001; Uher et al. 2012); • Chronic course over 10 years (Moos & Cronkite 1999). 2) Anhedonia and amotivation are poorly addressed by first- line treatments (Calabrese et al., 2014; Craske et al., 2019). 3) Anhedonia predicts poor response to first-line pharmacological (e.g., SSRI; Vrieze et al., 2013) and psychological (e.g., CBT; McMakin et al. 2012) treatments as well as TMS (e.g., Downar et al., 2014). Borrowing from the “Traditional” Approach…. 1) Since anhedonia has been associated with: • Reduced functional, structural, and neurochemical markers within DA-rich regions along the mesocorticolimbic pathways (e.g., ventral and dorsal striatum) (e.g., Auerbach et al., 2017; Gabbay et al., 2017; Keedwell et al., 2005; Pecina et al., 2017); 2) Dopamine plays a key role in several reward-related functions (incentive motivation, reinforcement learning) 1) + 2) Patients with anhedonic phenotypes might preferentially benefit from treatments hypothesized to increase DA signaling. Parsing Reward Processing: From Hedonics to Motivated Behavior Barch et al., 2015 Barch et al., 2015 Reward Learning Barch et al., 2015 Reward Learning As a DA-sensitive Phenotype Probabilistic Reward Task 11.5 vs.
    [Show full text]
  • Imaging Modalities in Differential Diagnosis of Parkinson's Disease: Opportunities and Challenges
    Mortezazadeh et al. Egyptian Journal of Radiology and Nuclear Medicine Egyptian Journal of Radiology (2021) 52:79 https://doi.org/10.1186/s43055-021-00454-9 and Nuclear Medicine REVIEW Open Access Imaging modalities in differential diagnosis of Parkinson’s disease: opportunities and challenges Tohid Mortezazadeh1 , Hadi Seyedarabi2 , Babak Mahmoudian3 and Jalil Pirayesh Islamian1* Abstract Background: Parkinson’s disease (PD) diagnosis is yet largely based on the related clinical aspects. However, genetics, biomarkers, and neuroimaging studies have demonstrated a confirming role in the diagnosis, and future developments might be used in a pre-symptomatic phase of the disease. Main text: This review provides an update on the current applications of neuroimaging modalities for PD diagnosis. A literature search was performed to find published studies that were involved on the application of different imaging modalities for PD diagnosis. An organized search of PubMed/MEDLINE, Embase, ProQuest, Scopus, Cochrane, and Google Scholar was performed based on MeSH keywords and suitable synonyms. Two researchers (TM and JPI) independently and separately performed the literature search. Our search strategy in each database was done by the following terms: ((Parkinson [Title/Abstract]) AND ((“Parkinsonian syndromes ”[Mesh]) OR Parkinsonism [Title/Abstract])) AND ((PET [Title/Abstract]) OR “SPECT”[Mesh]) OR ((Functional imaging, Transcranial sonography [Title/Abstract]) OR “Magnetic resonance spectroscopy ”[Mesh]). Database search had no limitation in time, and our last update of search was in February 2021. To have a comprehensive search and to find possible relevant articles, a manual search was conducted on the reference list of the articles and limited to those published in English.
    [Show full text]
  • LBT-999) As a Highly Promising Fluorinated Ligand for the Dopamine Transporter
    JPET Fast Forward. Published on December 9, 2005 as DOI: 10.1124/jpet.105.096792 JPET FastThis Forward.article has not Published been copyedited on and December formatted. The 9, final 2005 version as DOI:10.1124/jpet.105.096792may differ from this version. JPET #96792 Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2β- carbomethoxy-3β-(4’-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter Sylvie Chalon, Hakan Hall, Wadad Saba, Lucette Garreau, Frédéric Dollé, Christer Halldin, Patrick Emond, Michel Bottlaender, Jean-Bernard Deloye, Julie Helfenbein, Jean-Claude Madelmont, Sylvie Bodard, Zoïa Mincheva, Jean-Claude Besnard and Denis Guilloteau Inserm, U619, Tours, France; Université François-Rabelais de Tours, France (S.C., L.G., P.E., Downloaded from S.B., Z.M., J.-C.B., D.G.); Karolinska Institutet, Stockholm, Sweden (H.H., C.H.) ; SHFJ, CEA/DSV, Orsay, France (W.S., F.D., M.B.); Laboratoires Cyclopharma, Saint-Beauzire, France (J.-B.D.); Orphachem, Clermont-Ferrand, France (J.H.); Inserm U484, Clermont- jpet.aspetjournals.org Ferrand, France (J.-C.M.) at ASPET Journals on September 30, 2021 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on December 9, 2005 as DOI: 10.1124/jpet.105.096792 This article has not been copyedited and formatted. The final version may differ from this version. JPET #96792 Running title: Pharmacological characterization of LBT-999 Corresponding author: Sylvie Chalon, Inserm U619;
    [Show full text]
  • Functional Effects of Dopamine Transporter Gene Genotypes on in Vivo Dopamine Transporter Functioning: a Meta-Analysis
    Molecular Psychiatry (2014) 19, 880–889 & 2014 Macmillan Publishers Limited All rights reserved 1359-4184/14 www.nature.com/mp ORIGINAL ARTICLE Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis SV Faraone1, TJ Spencer2, BK Madras3,4, Y Zhang-James1 and J Biederman2 Much psychiatric genetic research has focused on a 40-base pair variable number of tandem repeats (VNTR) polymorphism located in the 30-untranslated region (30UTR) of the dopamine active transporter (DAT) gene (SLC6A3). This variant produces two common alleles with 9- and 10-repeats (9R and 10R). Studies associating this variant with in vivo DAT activity in humans have had mixed results. We searched for studies using positron emission tomography (PET) or single-photon emission computed tomography (SPECT) to evaluate this association. Random effects meta-analyses assessed the association of the 30UTR variant with DAT activity. We also evaluated heterogeneity among studies and evidence for publication bias. We found twelve studies comprising 511 subjects, 125 from PET studies and 386 from SPECT studies. The PET studies provided highly significant evidence that the 9R allele was associated with increased DAT activity in human adults. The SPECT studies were highly heterogeneous. As a group, they suggested no association between the 30UTR polymorphism and DAT activity. When the analysis was limited to the most commonly used ligand, [123I]b-CIT, stratification by affection status dramatically reduced heterogeneity and revealed a significant association of the 9R allele with increased DAT activity for healthy subjects. In humans, the 9R allele of the 30UTR polymorphism of SLC6A3 regulates dopamine activity in the striatal brain regions independent of the presence of neuropsychiatric illness.
    [Show full text]